Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company’s CEO, has purchased a total of 347,100 ordinary shares of £0.00037
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company’s CEO, has purchased a total of 347,100 ordinary shares of £0.00037 (“Ordinary Shares”) via three transactions which are summarised in the table below (the “Transactions”).
|
Date of Transaction |
Number of Ordinary Shares purchased |
Price per Ordinary Share |
|
13 December 2019 |
100,000 |
20.22p |
|
16 December 2019 |
100,000 |
20.02p |
|
27 December 2019 |
147,100 |
23.87p |
Following this Transactions, Mr Hullihen holds a beneficial interest in 2,928,899 Ordinary Shares, representing 2.56 per cent. of the Company's issued share capital with voting rights.
Enquiries:
|
Polarean Imaging plc |
||||
|
Richard Hullihen, Chief Executive Officer |
Via Walbrook PR |
|||
|
Richard Morgan, Chairman |
|
|||
|
|
||||
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|||
|
David Hignell / Soltan Tagiev (Corporate Finance) |
||||
|
Vadim Alexandre / Rob Rees (Corporate Broking) |
||||
|
|
||||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com |
|||
|
Anna Dunphy / Paul McManus |
Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 |
|||